Quick Answer: A Trial Protocol Is Not a Trial Result
A 2026 protocol describes the SOLE randomized trial, which plans to compare cushioned insoles with visually similar sham insoles in adults with first metatarsophalangeal joint osteoarthritis. The paper explains a research design; it does not report clinical outcomes or evaluate VALSOLE products.
What Happened
The planned study will randomize participants to cushioned or sham insoles for 12 weeks and assess participant-reported outcomes. Publishing the protocol makes the intended comparison and outcome plan visible before results are known.
Why It Matters Now
Insole headlines often blur the line between a study launch and a completed result. A sham-controlled design can be useful because it tests an intervention against a comparison condition, but the design alone cannot establish benefit.
Consumer Decision Context
- Read protocol, pilot and completed-trial headlines as different evidence stages.
- Do not infer that a clinical research insole matches a retail product.
- For a diagnosed condition, use individualized clinical advice rather than a general shopping article.
VALSOLE Support Path
The Insoles Complete Guide explains general selection factors such as shoe fit and daily use. Readers can then browse the Insoles collection or use Quick Match.
What This Means for Readers
The useful current news is methodological: the study has drawn a clearer comparison plan. Results, limitations and applicability need to wait for the completed trial.
Sources
- Journal of Foot and Ankle Research / PubMed. Cushioned Insoles for First Metatarsophalangeal Joint Osteoarthritis: Protocol for the SOLE Randomised Controlled Trial. September 2026.
- Journal record. DOI: 10.1002/jfa2.70185.

